-
ESTABLISHING A LEADER IN CELL-BASED IMMUNOTHERAPIES BUILT ON DECADES OF EXPERTISE IN THE FIELD OF ALLOGENEIC DENDRITIC CELL BIOLOGY
Immunicum is listed on NASDAQ Stockholm under the ticker IMMU
About us
Developing innovative cancer immunotherapies
Immunicum is advancing novel cell-based approaches to treat blood-borne and solid tumors.
Learn more
Press Releases
Immunicum Presents Data on Clinical Program DCP-001 at the European Hematology Association (EHA) 2021 Virtual Congress
11 Jun 2021Immunicum Announces Presentations at the European Hematology Association (EHA) 2021 Virtual Congress
12 May 2021Report from the Annual General Meeting of Immunicum AB (publ) on 4 May 2021
04 May 2021
News
-
European Hematology Association (EHA) 2021 Virtual Meeting – Posters
11 Jun 2021 -
Immunicum Corporate Presentation at Redeye Growth Day 2021
8 Jun 2021 -
Immunicum Investor Event on April 22, 2021 at 1:00 pm CET
19 Apr 2021 -
Virtual Investor Event Materials
8 Dec 2020 -
Transaction Webcast Presentation
19 Nov 2020
